gtag('config', 'AW-16657171524');
Starting August 1st, 2024, Eurobio Scientific is manufacturing and selling IVD kits for: EndoPredict® (Breast Cancer) / Prolaris® (Prostate Cancer) Read more
Which patients with ER positive/HER2 negative breast cancer will benefit from chemotherapy? EndoPredict provides 10 years’ personalized chemobenefit for every patient to guide decision-making.
Prediction of chemotherapy benefit by EndoPredict was shown in a large cross-cohort study with over 3,700 pre- and postmenopausal patients with ER positive/HER2 negative, node positive and node negative breast cancer.
Fill out the form below to download your free copy of the clinical summary to learn more about this key study.